Skip to main content

Allergan earnings: Drug maker looks for a way back after major patent blow

The company lost a patent court decision on its second-most valuable drug, which could cause major revenue loss as early as next year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.